Overexpression of UCP2 in multiple human cancer cell lines has consistently shown to favor a highly glycolytic phenotype, inhibits ROS accumulation, and prevents apoptosis after exposure to chemotherapeutic agents (38–40). This evidence concerns the gene UCP2 and cancer.